Immunocore Holdings Limited (IMCR)
|Net Income (ttm)||n/a|
|Trading Day||June 21|
|Day's Range||39.26 - 40.84|
|52-Week Range||30.92 - 61.99|
P RESS RELEASE
Coinbase's IPO was spectacular. But these stocks with recent IPOs might have better long-term prospects.
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary Phase 3 data comparing tebentafusp (IMCgp100) with investigator's choice subject of oral plenary
The FDA has designated Breakthrough Therapy status to Immunocore Holdings PLC's (NASDAQ: IMCR) tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive in adult patients with unresectable or met...
Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disea... [Read more...]
|IPO Date |
Feb 5, 2021
Bahija Jallal, Ph.D.
|Stock Exchange |
|Ticker Symbol |
In 2020, Immunocore's revenue was 30.11 million, an increase of 17.32% compared to the previous year's 25.67 million. Losses were -74.09 million, -28.71% less than in 2019.
The average 12-month stock price forecast for Immunocore is 51.50, which is an increase of 31.18% from the latest price.